Koichi Ito

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Epithelial Mesenchymal Transition

Cell Cycle Arrest

Transcription Factor

Top Venues

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Koichi Ito, Ibuki Harada, Criseyda Martinez, Katsutoshi Sato, Eunjee Lee, Elisa Port, Jessica H Byerly, Anupma Nayak, Ekta Tripathi, Jun Zhu, Hanna Y Irie
MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases. Cancer research communications 4 (3) (2024)
Koichi Ito, Ibuki Harada, Criseyda Martinez, Katsutoshi Sato, Eunjee Lee, Elisa Port, Jessica H Byerly, Anupma Nayak, Ekta Tripathi, Jun Zhu, Hanna Y Irie
MARCH2, a novel oncogene-regulated SNAIL E3 ligase, suppresses triple negative breast cancer metastases. Cancer research communications (2024)
Koichi Ito, Ibuki Harada, Criseyda Martinez, Katsutoshi Sato, Eunjee Lee, Elisa Port, Jessica H Byerly, Anupma Nayak, Ekta Tripathi, Jun Zhu, Hanna Y Irie
MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases. Cancer research communications 4 (3) (2024)
Koichi Ito, Ibuki Harada, Criseyda Martinez, Katsutoshi Sato, Eunjee Lee, Elisa Port, Jessica H Byerly, Anupma Nayak, Ekta Tripathi, Jun Zhu, Hanna Y Irie
MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases. Cancer research communications 4 (3) (2024)
Koichi Ito, Ibuki Harada, Criseyda Martinez, Katsutoshi Sato, Eunjee Lee, Elisa Port, Jessica H Byerly, Anupma Nayak, Ekta Tripathi, Jun Zhu, Hanna Y Irie
MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases. Cancer research communications 4 (3) (2024)
Jack Carter, Michael Hulse, Monisha Sivakumar, Jessica Burtell, Venkat Thodima, Min Wang, Anjana Agarwal, Komali Vykuntam, Jacob Spruance, Neha Bhagwat, Joseph Rager, Bruce A Ruggeri, Peggy Scherle, Koichi Ito
PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies. Cancer research communications (2023)